Home remedies for conjunctivitis, eye inflammations: Try these Ayurvedic principles for quick relief
Want to keep your eyes bright and beautiful? Introduce these Ayurvedic practices into your everyday routine to effectively ...
Hosted on MSN13d
What Causes Itchy Eyes?
Whether acute (short-term) or chronic (long-term), itchy eyes can be an uncomfortable experience and affect your quality of life. However, home remedies and medications can often treat the discomfort ...
EBGLYSS for eczema: What to know about the newly FDA-approved drug from Eli Lilly
The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...
Got a Case of the Sniffles? These Are the Best Seasonal Allergy Medicines and Remedies on Amazon
We’ve pulled together a list of the best allergy medicine on Amazon, so you can be ready to tackle symptoms before they get ...
Daily9d
FDA Approves lebrikizumab for treatment of atopic dermatitis
The US food and Drug Administration has approved lebrikizumab for treatment of atopic dermatitis in adults and children ages ...
The Valdosta Daily Times12d
Welcome to “Wita”: Claritin® Aims to Take the ‘Itch’ Out of Wichita, the #1 Allergy Capital in the U.S., Just in Time for Fall Allergy Season
Itching for allergy relief this fall? So are residents of Wichita, Kansas, the No. 1 allergy capital in the United States, according to the Asthma and Allergy Foundation of America (AAFA). This ...
'I spent months going to doctor with itchy rash - I had no idea it was life-threatening'
“Both of the things I was diagnosed with are equally life threatening,” she says. “Cancer is physically destructive and ...
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and ...
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in ...